Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China’s Hutchison MediPharma Freezes Development Of Cancer Drug, Signs Development Deal With Janssen

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Shanghai-headquartered Hutchison MediPharma has frozen development of a cancer drug after Phase II clinical trials conducted in China produced inconclusive data on the efficacy of the medicine, according to company executives

You may also be interested in...



Hutchison Medipharma Initiates Phase I Trials Of Cancer-fighting Candidate Sulfatinib In China

SHANGHAI - Chinese innovative drug developer Hutchison MediPharma has initiated Phase I clinical trials in China for its anti-cancer drug candidate, HMPL-012 (sulfatinib), the company said May 6

Hutchison Medipharma Initiates Phase I Trials Of Cancer-fighting Candidate Sulfatinib In China

SHANGHAI - Chinese innovative drug developer Hutchison MediPharma has initiated Phase I clinical trials in China for its anti-cancer drug candidate, HMPL-012 (sulfatinib), the company said May 6

China's Hutchison MediPharma Phase IIb Trials In Ulcerative Colitis Meet Primary, Secondary Endpoints

SHANGHAI - Chinese biotech Hutchison MediPharma announced Nov. 5 that its Phase IIb global clinical trial of lead candidate HMPL-004 in patients with ulcerative colitis, a form of inflammatory bowel disease, met primary and key secondary endpoints

Related Content

UsernamePublicRestriction

Register

SC066821

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel